IgAN: New Guidelines and Emerging Treatments to Reach Proteinuria Goals and Slow Decline in Kidney Function

Target Audience
The intended audience for this activity are nephrologists. The secondary audiences are primary care/internal medicine physicians.

Learning Objectives
At the conclusion of this activity, participants will be able to:

IgAN: New Guidelines and Emerging Treatments to Reach Proteinuria Goals and Slow Decline in Kidney Function

Describe the disease burden experienced by children and adults with IgAN, including the consequences of late diagnoses and the limitations of current therapies
Define the pathophysiology of IgAN, specifically as it relates to the role of ET1 and RAAS on proteinuria regulation
Describe the mechanism of action, efficacy and safety data, and potential place in care of emerging dual AT1/ETA blockers to reduce proteinuria to clinically meaningful goals and slow renal function decline in IgAN
Apply updated KDIGO guidelines for the diagnosis of IgAN, assessing patient risk for rapid disease progression using clinical history, laboratory findings, and renal biopsy